Biohaven Pharmaceuticals, Inc

Please note: The information displayed on this page might be outdated.

Biohaven Pharmaceuticals, Inc: Commercial-stage, focused on neurological & neuropsychiatric diseases; CGRP receptor antagonist, glutamate modulation, and MPO platforms. NURTEC® ODT approved 1Q20 acute treatment of migraine and 1Q21 preventive treatment of migraine; $136m 3Q21 revenues. Plan to complete enrollment of verdiperstat for the treatment of ALS in 4Q21, and report topline of troriluzole in Spinocerebellar Ataxia in 2H22.

Sector/Industry:

Healthcare/Biotechnology

Characteristics:

Based in...

US - New England

Clinical Stage

Marketed, Phase III

Disease Space

Central Nervous System, Rare Disease

Finance

Revenues

Industry

Biotechnology

Listing

Public, USA

Market Cap

1B +

Therapeutic Modalities

Small Molecule

Website:

http://biohavenpharma.com/

Profiles:

Address:

215 Church Street
New Haven, CT 06510
United States

Presentation:

Please reach out to Solebury Strategic Communications to request a presentation

More info:

Send Message to Request Information

My account:

Company Participants at Solebury Trout Hamptons CEO Roundtable 2021

Vlad Coric, M.D., Chief Executive Officer

Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...

Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.